Featured Post from ChristianaCare

ChristianaCare Scientists Show for the First Time That Tumor Cells Can Manipulate the Body’s Natural Antibody Response to Triple Negative Breast Cancer

Apr 26, 2022

4 min

Findings point to potential new therapeutic targets for this highly aggressive, drug-resistant breast cancer subtype


In breakthrough research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, scientists have discovered that a protein secreted by tumor cells can switch off the body’s natural defenses against triple negative breast cancer (TNBC).


The study, led by Jennifer Sims-Mourtada, Ph.D., lead research scientist at the Cawley Center for Translational Cancer Research (CTCR), at the Graham Cancer Center, is reported in The Journal of Translational Medicine, available online.


“What we found is that TNBC tumor cells can effectively shut down the body’s defense systems against the tumor by secreting a type of protein called IL-10,” Dr. Sims-Mourtada said.


“The presence of this immune system protein forces the antibodies that would normally be created to attack the tumor to become non-reactive and not do what they are supposed to do.”


The study was initiated in partnership with The Wistar Institute of Philadelphia, Pennsylvania, in collaboration with the late Raj “Shyam” Somasundaram, Ph.D., a cell biologist at the Melanoma Research Center.


“Dr. Sims-Mourtada and her team have brought us tantalizingly close to understanding what drives the aggressive nature of triple negative breast cancer, a treatment-starved disease that disproportionately affects Delaware women,” said Nicholas J. Petrelli, M.D., Bank of America endowed medical director of the Helen F. Graham Cancer Center & Research Institute.


“Their work underscores our belief that scientific collaborations such as this one between our Cawley CTCR clinicians and Wistar scientists can smooth the way for new findings to become effective therapies, especially for hard-to-treat and aggressive forms of cancer like TNBC.”


Understanding the mechanism behind TNBC

Delaware ranks highest in the nation for incidence of triple negative breast cancer. TNBC is an aggressive form that affects Black women at twice the rate of white women with poorer outcomes. Patients have higher rates of early recurrence than other breast cancer subtypes, particularly in the first five years after diagnosis. Currently there is no targeted therapy for TNBC.


“One of our missions within the Cawley CTCR is to understand the mechanisms behind TNBC and find a treatment for it,” Dr. Sims-Mourtada said. “Our study sheds new light on what is prompting the body’s immune response to the cancer cells and offers clues to potential new therapeutic targets.”


Normally it is the job of the B cells to regulate the immune response against foreign invaders like cancer. Among other jobs, they control inflammation at the site of an attack by releasing proteins including IL-10 to signal the defender cells to stand down.


“Previously it was thought that the immune cells were the ones to express IL-10 to regulate themselves,” Dr. Sims-Mourtada said. “But our study shows that the tumor cells also release this protein, which means they are driving how the immune system behaves.”


Within the tumor microenvironment, IgG4 is one of four antibody subclasses expressed and secreted by B cells. Whereas another type of antibody would urge the immune system to press on with the attack, activation of IgG4 signals the job is done.


TNBC and activation of IgG4

“Our findings support that TNBC may create a tumor environment that supports activation of IgG4, and messaging from IL10 is triggering the switch,” Dr. Sims-Mourtada said.


As previously reported with other cancers, such as melanoma, this study confirms that the presence of IgG4-positive B cells within the tumor associates with advanced disease increased recurrence and poor overall breast cancer survival. It is also possible that IL-10 expression by tumor cells may also be a cause of poor outcomes in TNBC, and this may be independent of IgG4+ B cells.


“At this point, we don’t know what causes tumor cells to start secreting IL-10, but we know that B cell-tumor cell interactions are involved,” Dr. Sims-Mourtada said.


“We still have to look at what is really going on in the B cell population to determine which subtypes of B cells are affected by this tumor crosstalk and why some forms of TNBC express IL-10 (the ones with poor outcomes) and others do not.


“We think that the presence or absence of other immune cells in the microenvironment may affect how B cells interact with tumor cells to drive IL-10 expression,” she said.


Resources for the study, including blood and tissue samples from consenting patients, were obtained through the Graham Cancer Center’s Tissue Procurement program. Interestingly, in a small subset of samples, the researchers found that IL-10 expression was significantly higher in Black patients than non-Hispanic white patients. These findings need to be confirmed in a larger more diverse population with different TNBC subtypes.


Understanding tumor-infiltrating B cells

“Our growing understanding of the contribution of IgG4+ cells to the immune microenvironment of TNBC and what drives IL-10 expression may reveal ways in which tumor-infiltrating B cells can contribute to tumor growth and provide new targets to increase the immune response to TNBC,” Dr. Sims-Mourtada said.


As partners for more than a decade, Graham Cancer Center research clinicians and Wistar scientists collaborate across disciplines to translate cancer research into more effective therapies for patients everywhere. In addition to providing high-quality, viable tissue samples for Wistar research studies, Graham Cancer Center clinicians actively participate in concept development, sharing their unique understanding of the everyday patient experience.


You might also like...

Check out some other posts from ChristianaCare

2 min

ChristianaCare Breaks Ground on New Middletown Health Center

ChristianaCare today broke ground on its new Health Center at Middletown, marking a major milestone in bringing expanded, affordable and exceptional care to families in southern New Castle County and northern Kent County. The center is expected to open in spring 2027. The $92.3 million project reflects a deep investment in the health and vitality of the region and is part of ChristianaCare’s larger plan, announced in July, to invest more than $865 million in Delaware over the next three years. The 87,000-square-foot Health Center will rise at 621 Middletown Odessa Road, next to ChristianaCare’s existing freestanding emergency department. Designed as a modern, multidisciplinary hub, the facility will expand access to comprehensive services and create more than 70 new full-time jobs, boosting both community health and the local economy. “Today we take an exciting step forward for Delaware, as part of ChristianaCare’s $865 million investment to expand access and strengthen health across our state,” said Janice E. Nevin, M.D., MPH, President and CEO of ChristianaCare. “This new health center is a promise to Delawareans: that they will have access to exceptional care close to home, delivered with love and excellence. More than a building, it represents our vision for healthier communities, our deep commitment to those we serve, and a future where every neighbor can thrive.” A Holistic, Patient-Centered Experience The ChristianaCare Health Center at Middletown will bring together a wide range of services in one convenient location, including: Primary and specialty care. Women’s health, behavioral health, oncology, cardiovascular care, pediatrics, neurology, imaging, diagnostics and lab testing. Hybrid exam rooms with interactive digital tools that allow family members to join virtually. Calming waiting areas with sensory-sensitive design features, plus friendly floor ambassadors to help patients navigate the building. Healing environments that include walking trails and abundant natural light. “We are designing care around people, not around appointments or buildings,” said Pauline Corso, president of Ambulatory Network Continuity and Growth at ChristianaCare. “From easy parking to advanced care coordination, every detail of this new center is aimed at making health care more welcoming, more connected and more human.” A Community Partnership ChristianaCare has been part of the Middletown community since 2009, when it first acquired the land that is now home to the freestanding emergency department. Last year, that facility provided care for more than 32,000 patient visits. “This groundbreaking is a proud moment for our town,” said Ken Branner, mayor of Middletown. “ChristianaCare has been a trusted partner for many years, and this new facility shows a lasting commitment to our residents. It will bring top-quality care closer to home and create good jobs right here in our community.”

2 min

ChristianaCare’s Center for Virtual Health Earns NCQA Accreditation, Setting a National Standard in Virtual Care

ChristianaCare’s Virtual Primary Care practice at the Center for Virtual Health has earned full accreditation from the National Committee for Quality Assurance (NCQA), placing it among the first health systems in the nation to achieve this distinction. ChristianaCare was one of only 18 organizations invited to participate in NCQA’s inaugural pilot program in 2023 to develop the Virtual Care Accreditation. The recognition affirms ChristianaCare’s leadership role in shaping the future of health care and its commitment to delivering accessible, equitable and patient-centered care through innovative digital platforms. “This accreditation is a powerful validation of our vision to reimagine health care,” said Sarah Schenck, M.D., FACP, executive director of ChristianaCare’s Center for Virtual Health. “We’ve built a model that meets people where they are—at home, at work or on the go—with care that is personal, proactive and powered by love and excellence.” What Accreditation Means for Patients NCQA accreditation underscores that ChristianaCare’s Center for Virtual Health meets rigorous standards for: Clinical quality and safety: clear care protocols, escalation pathways and outcome monitoring. Access and equity: technology, language and disability-inclusive design that extends care to more people. Data privacy and security: strong safeguards to protect personal health information. ChristianaCare’s participation in NCQA’s pilot helped shape the benchmarks now used nationwide. The center delivers comprehensive virtual primary care through a multidisciplinary team that includes physicians, nurses, nurse practitioners, behavioral health specialists, pharmacists and patient digital ambassadors. Virtual Care by the Numbers In 2024, ChristianaCare’s Center for Virtual Health provided more than 7,500 patient visits, reflecting both rapid growth and strong demand for its virtual-first model. Services are offered at no copay to ChristianaCare caregivers and their dependents, while availability continues to expand across Delaware and the region “At ChristianaCare, we believe virtual care isn’t just a convenience, it’s a catalyst for better health outcomes,” said Brad Sandella, D.O., MBA, medical director, Ambulatory Care for the Center for Virtual Health. “This accreditation affirms our commitment to innovation and excellence. We’re proud to be among the pioneers defining what high-quality virtual care looks like in America.” Beginning in 2026, ChristianaCare will expand its Virtual Primary Care practice, giving a broader consumer audience convenient access to primary care. At that time, the service will be covered by most insurance carriers and continue to feature dedicated providers in areas such as behavioral health and neurology. ChristianaCare will also continue working with NCQA and other partners to advance best practices nationwide.

4 min

First in Delaware to Offer Breakthrough Tricuspid Valve Disease Treatments

For the first time in Delaware, patients with tricuspid valve disease have access to two new FDA-approved, minimally invasive procedures that can repair or replace a failing heart valve without the need for open-heart surgery. The tricuspid valve helps keep blood moving in the right direction through the heart. When it doesn’t close properly — a condition known as tricuspid valve regurgitation — blood leaks backward, forcing the heart to work harder. Over time, patients can experience fatigue, shortness of breath and swelling in the legs and ankles. ChristianaCare’s Center for Heart & Vascular Health is among the first in the nation and the first in the state to offer these advanced procedures, which can restore valve function and improve quality of life. “ChristianaCare continues to innovate in the area of non-surgical valve procedures,” said Kirk Garratt, M.D., MSc, medical director of the Center for Heart & Vascular Health. “We now offer every FDA-approved therapy for tricuspid valve disease, which means we can tailor treatment to each patient and choose the option that best fits their condition.” New Procedures Offer Hope for Patients ChristianaCare offers these minimally invasive procedures to treat tricuspid valve regurgitation: TriClip, which repairs a leaky tricuspid valve. A staple-like clip is attached to the flaps of the valve that don’t close properly, which stops the valve from leaking. EVOQUE, which replaces a faulty tricuspid valve. When the new valve is placed, it uses the patient’s own tricuspid valve as an anchoring system. The new valve takes over for the leaky valve, correcting the problem. “Most of our patients with tricuspid valve disease are older adults, and they really do not desire to travel to Philadelphia for treatment,” said Erin Fender, M.D., an interventional cardiologist at the Center for Heart & Vascular Health. ChristianaCare’s tricuspid valve disease program enables patients to stay in Delaware for treatment and receive this leading-edge care. Fender and interventional cardiologist James Hopkins, M.D., performed ChristianaCare’s first TriClip procedure in August. In September, they performed ChristianaCare’s first EVOQUE procedure. Minimally Invasive, Maximum Impact During both procedures, an IV catheter is inserted into a vein at the top of the leg. A hollow tube is threaded through the IV and into the heart, allowing the clip or replacement valve to access the tricuspid valve. The entire procedure is guided by echocardiogram and generally takes one to two hours. “Patients are usually up and walking later that evening or the next morning, depending on what time of day the procedure was done,” Fender said. “They’re typically discharged the following day.” In the past, open-heart surgery was the only treatment for tricuspid valve disease, but patients with severe symptoms usually weren’t good surgical candidates. “When I was a fellow, I did research focused on tricuspid regurgitation at a time when patients really had no therapeutic options,” Fender said. “Now, being able to offer people therapy that’s so safe and effective, with minimal downtime afterwards, is absolutely transformative to our patients. It’s delightful to see the evolution.” Expanding the Toolbox of Innovation The TriClip and EVOQUE are two of the most recent minimally invasive procedures performed at the Center for Heart & Vascular Health. Other recent innovative, minimally invasive heart and vascular procedures include: Pulsed field ablation for atrial fibrillation. A-fib arises when abnormal heart tissue mistakenly prompts electrical impulses, causing heart palpitations, chest pain and shortness of breath. Pulsed field ablation safely destroys the abnormal tissue quicker and more consistently than other treatments, such as freezing (cryoablation) or heating (radiofrequency ablation). Genicular artery embolization for mild to moderate knee pain. Osteoarthritis can cause inflammation and pain within the knee, which can limit a patient’s mobility. Genicular artery embolization pinpoints areas of inflammation within the knee, and tiny bead-like particles are placed within the blood vessels to block blood flow to those areas. The procedure reduces pain and improves mobility. National Recognition for Excellence ChristianaCare’s Center for Heart & Vascular Health continues to earn national recognition as one of the nation’s premier destinations for cardiovascular care. Most recently, the Center received the HeartCare National Distinction of Excellence award from the American College of Cardiology for the 6th consecutive year. This award honors hospitals that consistently deliver superior medical, surgical and radiologic care aligned with the most rigorous standards of the American College of Cardiology. The award reflects ChristianaCare’s commitment to ensuring patients receive the best, evidence-based care for every cardiovascular need. That excellence is further affirmed by U.S. News & World Report, which named ChristianaCare a High Performing hospital in its 2025—2026 Best Hospitals rankings for aortic valve surgery, heart bypass surgery and heart failure. The Center for Heart & Vascular Health is among the largest and most advanced programs on the East Coast, uniquely integrating cardiac surgery, vascular surgery, vascular interventional radiology, cardiology and interventional nephrology in one location. In 2024, its expert clinical teams performed nearly 200,000 patient procedures, underscoring the depth of experience and patient-centered care that set ChristianaCare apart.

View all posts
Powered by